The experimental HIV vaccine phase I clinical trial has a significant effect 97% of vaccinators have a targeted immune response

February 24, 2021 // --Recently, the International AIDS Vaccine Initiative (IAVI) and the Scripps Institute jointly announced that a phase 1 clinical trial of a new vaccine strategy for the prevention of HIV infection has achieved extraordinary results.

William Schief, a researcher at the IAVI Neutralizing Antibody Research Center, said that this study proves the principles of a new HIV vaccine concept, which can also be applied to other pathogens.

This research has laid a certain foundation for later scientists to conduct more clinical trials.

Image source: Sergey Menis, IAVI

Mark Feinberg, MD, said that in view of the urgent need for an HIV vaccine to control the global pandemic of the disease, I think the relevant research results will have a broad impact on researchers engaged in HIV vaccines because they decide which research directions should be pursued.

For decades, HIV researchers have been seeking the "Holy Grail" that can stimulate the body's immune system to produce rare and powerful antibodies that can effectively neutralize different HIV strains.

The strategy of targeting B cells with specific characteristics is called "germline-targeting", because these young B cells can often display antibodies encoded by unmutated or germline genes; research The staff believes that this method is also suitable for studying other types of pathogens, such as influenza, dengue fever, Zika virus, hepatitis C virus and malaria.

The clinical trial called IAVI G001 was initiated by IAVI and was conducted in two locations: the University of Washington and the Fred Hutchinson Cancer Research Center; the researchers recruited 48 healthy adult volunteers, and the participants received a placebo or two doses.

Reference materials:

com/news/2021-02-experimental-hiv-vaccine-primed-immune.